MX352205B - Sistemas de expresion. - Google Patents
Sistemas de expresion.Info
- Publication number
- MX352205B MX352205B MX2013007716A MX2013007716A MX352205B MX 352205 B MX352205 B MX 352205B MX 2013007716 A MX2013007716 A MX 2013007716A MX 2013007716 A MX2013007716 A MX 2013007716A MX 352205 B MX352205 B MX 352205B
- Authority
- MX
- Mexico
- Prior art keywords
- expression system
- protein
- polynucleotide encoding
- induces
- variant
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000185 hemagglutinin Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000001775 anti-pathogenic effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- -1 cells Substances 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a una composición, caracterizada porque comprende un sistema de expresión que comprende un vector viral de adenovirus que comprende polinucleótidos que codifican proteínas de pneumovirus, y un portador y/o excipiente farmacéuticamente aceptable, en donde el sistema de expresión comprende un primer polinucleótido que codifica al menos una proteína, péptido o variante de los mismos, la cual induce una respuesta de células T, un segundo polinucleótido que codifica al menos una proteína, péptido o variante de los mismos, la cual induce una respuesta de células B anti-patógena, y un tercer polinucleótido que codifica una proteína, péptido o variante de los mismos, la cual induce una respuesta de células T, en donde: el pneumovirus es virus sincitial respiratorio humano (RSV); la proteína, péptido o variante de los mismos la cual induce una respuesta de células T, codificada por el primer polinucleótido, es una proteína no estructural y/o interna de RSV seleccionada del grupo que consiste de proteínas de Matriz M y M2; la proteína, péptido o variante de los mismos la cual induce una respuesta de células B anti-patógena, codificada por el segundo polinucleótido, es una proteína estructural y/o de superficie de RSV la cual es la proteína de fusión (F), y; la proteína, péptido o variante de los mismos la cual induce una respuesta de células T, codificad por el tercer polinucleótido, es una proteína no estructural y/o interna de RSV la cual es la nucleoproteína N; y el primer polinucleótido, el segundo polinucleótido y el tercer polinucleótido están enlazados de tal manera que se expresan como una poliproteína artificial.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2010/007995 WO2012089231A1 (en) | 2010-12-30 | 2010-12-30 | Paramyxovirus vaccines |
PCT/EP2011/074307 WO2012089833A2 (en) | 2010-12-30 | 2011-12-30 | Expression Systems |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013007716A MX2013007716A (es) | 2013-08-09 |
MX352205B true MX352205B (es) | 2017-11-13 |
Family
ID=45464575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007716A MX352205B (es) | 2010-12-30 | 2011-12-30 | Sistemas de expresion. |
Country Status (23)
Country | Link |
---|---|
US (4) | US20140141042A1 (es) |
EP (2) | EP3868397A1 (es) |
JP (2) | JP6324725B2 (es) |
KR (1) | KR102070463B1 (es) |
CN (1) | CN103442731B (es) |
AU (2) | AU2011351380A1 (es) |
BR (1) | BR112013016823A2 (es) |
CA (1) | CA2821111A1 (es) |
CY (1) | CY1124146T1 (es) |
DK (1) | DK2658573T3 (es) |
ES (1) | ES2869199T3 (es) |
HR (1) | HRP20210750T1 (es) |
HU (1) | HUE053986T2 (es) |
IL (1) | IL226551B (es) |
LT (1) | LT2658573T (es) |
MX (1) | MX352205B (es) |
NZ (1) | NZ610743A (es) |
PL (1) | PL2658573T3 (es) |
PT (1) | PT2658573T (es) |
RU (1) | RU2609645C2 (es) |
SG (2) | SG10201510760WA (es) |
SI (1) | SI2658573T1 (es) |
WO (2) | WO2012089231A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3842068A1 (en) | 2012-07-05 | 2021-06-30 | GlaxoSmithKline Biologicals S.A. | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
KR102435054B1 (ko) * | 2012-08-01 | 2022-08-22 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
DK2879702T3 (da) | 2012-08-01 | 2020-02-24 | Bavarian Nordic As | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) |
AU2013301312A1 (en) | 2012-08-06 | 2015-03-19 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against RSV and B. pertussis |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
ES2778899T3 (es) * | 2013-02-01 | 2020-08-12 | Medimmune Llc | Epítopos de proteína F del virus sincitial respiratorio |
US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
EP2969005B1 (en) | 2013-03-15 | 2019-10-16 | The Research Foundation for The State University of New York | Attenuated influenza viruses and vaccines |
AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
WO2015189425A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
EA038402B9 (ru) | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
MD3718565T2 (ro) * | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
GB201614485D0 (en) | 2016-08-25 | 2016-10-12 | Univ Oxford Innovation Ltd | Immunogenic composition |
WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
CN110036020A (zh) | 2016-12-09 | 2019-07-19 | 葛兰素史密丝克莱恩生物有限公司 | 具有狂犬病病毒抗原的黑猩猩腺病毒构建体 |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
GB201701239D0 (en) | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
CN107119064A (zh) * | 2017-02-21 | 2017-09-01 | 南京农业大学 | 重组枯草芽孢杆菌串联表达禽流感病毒ha抗原片段和pb1-f2蛋白 |
US20200299651A1 (en) | 2017-10-16 | 2020-09-24 | Glaxosmithkline Biologicals Sa | Simian adenoviral vectors with two expression cassettes |
CA3079048A1 (en) | 2017-10-16 | 2019-04-25 | Glaxosmithkline Biologicals Sa | Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof |
CN111328344A (zh) | 2017-10-16 | 2020-06-23 | 葛兰素史密丝克莱恩生物有限公司 | 增强的启动子 |
JP7274225B2 (ja) * | 2017-10-25 | 2023-05-16 | ノイスコム アーゲー | 真核細胞系統 |
BR112020012361A2 (pt) | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
WO2019239311A1 (en) | 2018-06-12 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2020014656A1 (en) * | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
CN109180820B (zh) * | 2018-09-19 | 2021-06-25 | 天康生物制药有限公司 | 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗 |
WO2020061443A2 (en) * | 2018-09-21 | 2020-03-26 | Board Of Regents Of The University Of Nebraska | Methods of making and using universal centralized influenza vaccine genes |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135312B2 (en) * | 1993-04-15 | 2006-11-14 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
US7655774B2 (en) | 2000-02-18 | 2010-02-02 | University Of Washington | Ancestral and COT viral sequences, proteins and immunogenic compositions |
EP1441762A1 (en) | 2001-09-28 | 2004-08-04 | University Of South Florida | Rsv gene expression vaccine |
MXPA04004876A (es) * | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
IL163646A0 (en) * | 2002-02-21 | 2005-12-18 | Vironovative Bv | Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus |
JP2005533861A (ja) * | 2002-07-25 | 2005-11-10 | メデュームン,インコーポレーテッド | 抗RSV、抗hMPV、および抗PIV抗体を使用するRSV、hMPV、およびPIVの治療法と予防法 |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
WO2005018539A2 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
WO2007126887A2 (en) * | 2006-03-27 | 2007-11-08 | The Government Of The United States Of America | Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use |
US9511134B2 (en) * | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
JP6199533B2 (ja) * | 2006-07-13 | 2017-09-20 | インスティチュート フォー アドバンスド スタディ | ウイルス阻害性ヌクレオチド配列およびワクチン |
WO2008028759A1 (de) | 2006-09-05 | 2008-03-13 | BSH Bosch und Siemens Hausgeräte GmbH | Bodendüse für hartböden |
US8772256B2 (en) * | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
JP2011521985A (ja) * | 2008-06-03 | 2011-07-28 | オカイロス アーゲー | Hcv感染の予防および治療のためのワクチン |
WO2010009277A2 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Immunogenic amphipathic peptide compositions |
WO2010077712A1 (en) * | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
DK3067064T3 (da) * | 2008-12-09 | 2020-06-08 | Novavax Inc | Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf |
JP2010168288A (ja) * | 2009-01-20 | 2010-08-05 | Yokohama City Univ | 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強 |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
-
2010
- 2010-12-30 WO PCT/EP2010/007995 patent/WO2012089231A1/en active Application Filing
-
2011
- 2011-12-30 AU AU2011351380A patent/AU2011351380A1/en not_active Abandoned
- 2011-12-30 ES ES11805889T patent/ES2869199T3/es active Active
- 2011-12-30 DK DK11805889.0T patent/DK2658573T3/da active
- 2011-12-30 CA CA2821111A patent/CA2821111A1/en active Pending
- 2011-12-30 RU RU2013135498A patent/RU2609645C2/ru active
- 2011-12-30 HU HUE11805889A patent/HUE053986T2/hu unknown
- 2011-12-30 LT LTEP11805889.0T patent/LT2658573T/lt unknown
- 2011-12-30 CN CN201180063466.0A patent/CN103442731B/zh active Active
- 2011-12-30 BR BR112013016823A patent/BR112013016823A2/pt not_active Application Discontinuation
- 2011-12-30 KR KR1020137017082A patent/KR102070463B1/ko active IP Right Grant
- 2011-12-30 PT PT118058890T patent/PT2658573T/pt unknown
- 2011-12-30 WO PCT/EP2011/074307 patent/WO2012089833A2/en active Application Filing
- 2011-12-30 MX MX2013007716A patent/MX352205B/es active IP Right Grant
- 2011-12-30 NZ NZ610743A patent/NZ610743A/en not_active IP Right Cessation
- 2011-12-30 US US13/976,873 patent/US20140141042A1/en not_active Abandoned
- 2011-12-30 SG SG10201510760WA patent/SG10201510760WA/en unknown
- 2011-12-30 SI SI201131973T patent/SI2658573T1/sl unknown
- 2011-12-30 PL PL11805889T patent/PL2658573T3/pl unknown
- 2011-12-30 JP JP2013546722A patent/JP6324725B2/ja active Active
- 2011-12-30 EP EP21158524.5A patent/EP3868397A1/en active Pending
- 2011-12-30 SG SG2013041348A patent/SG190919A1/en unknown
- 2011-12-30 EP EP11805889.0A patent/EP2658573B1/en active Active
-
2013
- 2013-05-23 IL IL226551A patent/IL226551B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/068,115 patent/US20170049879A1/en not_active Abandoned
-
2017
- 2017-01-13 JP JP2017004556A patent/JP2017079787A/ja active Pending
- 2017-05-12 AU AU2017203189A patent/AU2017203189B2/en active Active
-
2020
- 2020-02-25 US US16/800,384 patent/US11701422B2/en active Active
-
2021
- 2021-05-12 HR HRP20210750TT patent/HRP20210750T1/hr unknown
- 2021-05-17 CY CY20211100421T patent/CY1124146T1/el unknown
-
2023
- 2023-05-22 US US18/200,421 patent/US20240075125A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007716A (es) | Sistemas de expresion. | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
NZ731571A (en) | T cell receptors | |
MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
CL2014002166A1 (es) | Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia. | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
MX2014015002A (es) | Polipeptidos que tienen actividad de transgalactosilacion. | |
NZ629394A (en) | Synthetic brassica-derived chloroplast transit peptides | |
BR112012033404A2 (pt) | polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos. | |
EP2791362A4 (en) | PROTEINS WITH MRSA PBP2A AND FRAGMENTS THEREOF, NUCLEIC ACIDS FOR CODING THEREOF AND PREPARATIONS AND THEIR USE FOR THE PREVENTION AND TREATMENT OF MRSA INFECTIONS | |
BR112012033699A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
BR112013028407A2 (pt) | "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica". | |
BR112013017080A2 (pt) | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente | |
WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
EA201370076A1 (ru) | Иммуноглобулины-переносчики и их применение | |
MY150226A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
EA201491643A1 (ru) | Идентификация мутаций канал-опсина-2 (chop2) и способы применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA |
|
FG | Grant or registration |